Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

[1]  M. Suárez-Fariñas,et al.  Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. , 2014, The Journal of allergy and clinical immunology.

[2]  D. Leung,et al.  Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. , 2014, The Journal of allergy and clinical immunology.

[3]  M. Kubo,et al.  IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. , 2014, The Journal of investigative dermatology.

[4]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[5]  J. Bouwstra,et al.  TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. , 2014, The Journal of investigative dermatology.

[6]  G. Barton,et al.  Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis , 2014, The Journal of allergy and clinical immunology.

[7]  M. Suárez-Fariñas,et al.  Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. , 2014, The Journal of allergy and clinical immunology.

[8]  Nicholas Gulati,et al.  Mechanisms of contact sensitization offer insights into the role of barrier defects versus intrinsic immune abnormalities as drivers of atopic dermatitis , 2013, The Journal of investigative dermatology.

[9]  M. Suárez-Fariñas,et al.  Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.

[10]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[11]  V. Shi,et al.  IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis. , 2013, Cytokine.

[12]  M. Suárez-Fariñas,et al.  Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. , 2013, The Journal of allergy and clinical immunology.

[13]  M. Suárez-Fariñas,et al.  Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.

[14]  A. Bowcock,et al.  Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. , 2011, The Journal of allergy and clinical immunology.

[15]  U. Sivaprasad,et al.  Th2 Cytokines and Atopic Dermatitis. , 2011, Journal of clinical & cellular immunology.

[16]  M. Boguniewicz,et al.  Atopic dermatitis: a disease of altered skin barrier and immune dysregulation , 2011, Immunological reviews.

[17]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. , 2011, The Journal of allergy and clinical immunology.

[18]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. , 2011, The Journal of allergy and clinical immunology.

[19]  A. Bowcock,et al.  Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. , 2011, The Journal of allergy and clinical immunology.

[20]  M. Kaplan,et al.  Transcriptional regulation by STAT6 , 2011, Immunologic research.

[21]  M. Chren,et al.  Quality-of-life outcomes and measurement in childhood atopic dermatitis. , 2010, Immunology and allergy clinics of North America.

[22]  M. Kaplan,et al.  IL-4 Regulates Skin Homeostasis and the Predisposition toward Allergic Skin Inflammation , 2010, The Journal of Immunology.

[23]  J. Dieris-Hirche,et al.  Suizidgedanken, Angst und Depression bei erwachsenen Neurodermitikern , 2009, Der Hautarzt.

[24]  J. Redzic,et al.  Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. , 2008, The Journal of investigative dermatology.

[25]  N. Korman,et al.  Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. , 2008, Journal of the American Academy of Dermatology.

[26]  L. Doward,et al.  Quality of life of children with atopic dermatitis and their families , 2008, Current opinion in allergy and clinical immunology.

[27]  M. Boguniewicz,et al.  Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. , 2008, Clinical immunology.

[28]  K. Kaulback,et al.  The Socioeconomic Impact of Atopic Dermatitis in the United States: A Systematic Review , 2008, Pediatric dermatology.

[29]  J. Fowler,et al.  The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective. , 2007, Managed care interface.

[30]  K. Barnes,et al.  Cytokine modulation of atopic dermatitis filaggrin skin expression. , 2007, The Journal of allergy and clinical immunology.

[31]  Jon M Hanifin,et al.  A Population‐Based Survey of Eczema Prevalence in the United States , 2007, Dermatitis : contact, atopic, occupational, drug.

[32]  Erin G Harper,et al.  Efalizumab for severe atopic dermatitis: a pilot study in adults. , 2007, Journal of the American Academy of Dermatology.

[33]  H. Kimata.  Prevalence of suicidal ideation in patients with atopic dermatitis. , 2006, Suicide & life-threatening behavior.

[34]  Mayte Suárez-Fariñas,et al.  Harshlight: a "corrective make-up" program for microarray chips , 2005, BMC Bioinformatics.

[35]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[36]  H. Wulf,et al.  Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. , 2004, Acta dermato-venereologica.

[37]  K. Izuhara,et al.  IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. , 2002, Current drug targets. Inflammation and allergy.

[38]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.

[39]  A. Y. Finlay,et al.  Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis , 1991, The Lancet.